• Biocrates CEO Wulf Fischer-Knuppertz and Dr. Carmen Ludwig-Papst visit Professor Siqi Liu, one of the founders of BGI who is interested to develop the great opportunity for Biocrates technology in China.
    BGI is operating the China National Gene Bank for the Chinese government and represents Biocrates in China for kit and service offerings.

Wulf Prof Liu 1  Wulf Prof Liu 2

AAIC Researchers Report New Data on How Gut Bacteria and Lipid Metabolism May Influence Alzheimer’s and Other Brain Diseases:

Innsbruck, Austria – July 25th, 2018 – BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer’s Disease Metabolomics Consortium’s (ADMC) new breakthrough in Alzheimer’s research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer’s disease (AD). During the Alzheimer’s Association International Conference (AAIC), Chicago, USA, researchers reported new data on how gut bacteria and lipid metabolism may influence AD.

Full press release:

Press release (English)

Press release (German)

Biocrates is part of "Lange Nacht der Forschung"

Visit us on April 13, 2018 and learn all there is to know about Metabolomics!

 LNF18 Logo Datum

Biocrates announces the acquisition of Metanomics Health:

Innsbruck, Austria – January 3rd, 2018 – BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, announced today the acquisition of Metanomics Health GmbH. Metanomics Health is a metabolomics biomarker development and healthcare services specialist based in Berlin, Germany. 

Press release (English)
Press release (German)


Biocrates at the annual BioRN Conference

Click here to view the press release

Biocrates Celebrates 15 Years

In 2002, a new technology called „Metabolomics“ was still in its very early days. 4 professors (Adelbert Roscher, Günther Bonn, Hartmut Glossmann, Michael Popp) from Munich and Innsbruck were convinced that this new –omics technology had vast potential. Unlike other young companies in the field, the founders decided that Biocrates should focus on targeted, hypothesis driven research.
15 years later, Biocrates is among the main players in the field. Biocrates’ technology has proven easy to use and highly reliable. Biocrates’ analytical portfolio allows for the quantification of more than 600 endogenous metabolites, and has contributed to more than 700 scientific publications.
Biocrates thanks its clients and partners for their trust during the past 15 years. We are looking forward to shaping the future of personalized medicine together with you.


  • David Wishart (University of Alberta) visits the Oktoberfest in Munich with Biocrates CEO Wulf Fischer-Knuppertz, following Prof. Wishart's invited attendance at MSACL (Mass Spec at the Clinical Lab) in Salzburg, Austria.
    Wulf Wishart
  • President visits Biocrates booth at the International Conference of the Metabolomics Society in Brisbane, Australia.
    Brisbane 2017 s
    Dr. Jules Griffin, president of the Metabolomics Society, discusses about the
    future of Targeted Metabolomics with Dr. Wulf Fischer-Knuppertz
    (Biocrates CEO) and Dr. Matthias Scheffler (Biocrates CBO).

  • Biocrates wins prestigious Healthcare & Life Sciences AwardHealthCare Award 2016 Trophy blueback v2
    Biocrates has been named one of the winners of the Corporate Livewire’s Healthcare & Life Sciences Awards program (www.corporatelivewire.com), "Best Metabolic Phenotyping Solutions Provider". This prestigious program celebrates the most innovative and successful projects carried out around the world over the past 12 months in the healthcare industry.


  • Breastfeeding alters branched chain amino acid levels and protects mothers with gestational diabetes against type 2 diabetes: HelmholtzZentrum MünchenVisit Prof. Yixue Li
  • Visit to Prof. Yixue Li, Shanghai Industrial Technology Institute:
    Following the recent visit of Prof. Yixue Li (Director of the Medical Department of the Shanghai Industrial Technology Institute and Member of the Chinese Academy of Science), Biocrates' CEO Dr. Wulf Fischer-Knuppertz paid a visit to Prof. Li to discuss about an extended collaboration.

Austrian BIOCRATES Life Sciences AG, prime developer of state-of-the-art metabolite biomarker panels, is about to launch new editions of two of its well-established research kit products: AbsoluteIDQ® p180 and p150. Originally developed for use with the AB Sciex mass spectrometers, both kits are now available for Waters Xevo® TQ MS systems,  greatly increasing sample throughput and accelerating up analytical processes.



Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok Decline